ImMAGE Biotherapeutics Corporation, a Washington, DC and Bethesda, MD-based developer of multiple viable candidates to treat triple-negative breast cancer (TNBC), raised an initial seed round of $500k.
Coventry International of Hong Kong made the investment.
The company will use the capital to fund a research of a protein-targeted drug therapy designed to treat triple-negative breast cancer (TNBC).
Co-founded in 2015 and led by Chief Operating Officer Mahesh Narayanan and Chief Scientific Officer Anton Dormer, PhD., ImMAGE Biotherapeutics aims to deliver an alternative method to chemotherapy or surgical treatment of breast cancer. The company, an affiliate of PepVax, Inc., has eight promising candidates, which they expect to take into animal trials this spring.
Future funding will also accelerate these candidates through the research and development phase.